Read the control layer
microRNAs regulate gene expression upstream of many familiar downstream proteins and biomarkers. Their patterns can provide a different window into active biology.
Why miRoncol
The value is not one test. It is what the platform can keep learning.
miRoncol is building an intelligence layer around microRNA: measure a biologically important control system, recognize disease-associated patterns with computational analysis and add personal context as molecular histories grow.
Oncology is the first published application. Cardiovascular, neurodegenerative and metabolic applications remain research directions at different stages of development and validation.
BiologymicroRNA sits within a key gene-regulation layer
ComputationAI and analytics interpret patterns across measurements
TimeRepeated profiles can create personal molecular history
TranslationOne foundation can support multiple focused applications
A different category of company
From a single result to a learning system.
Traditional testing often ends when a result is delivered. miRoncol’s longer-term opportunity begins by preserving the measurement, connecting it to future evidence and learning what change means within the person’s own history.
Keep future possibilities open
Broad NGS profiling can preserve thousands of measurements that may be revisited as new research questions and disease signatures emerge.
Translate evidence into assays
When a defined signature is sufficiently validated, a focused PCR assay can support a narrower, more accessible application.
Add the dimension of time
A sequence of profiles can reveal stability, sustained change, an intervention point and a possible response,context unavailable from one isolated sample.
The first proof point
Oncology made the platform concrete.
The company’s first peer-reviewed branch demonstrates that a compact microRNA signature can distinguish disease-associated patterns across multiple studied cancer types while maintaining high specificity.
Evidence before assertion
Peer-reviewed papers in Cancers and Scientific Reports provide a public scientific record for the oncology research model.
Review performance and limitationsA focused consumer application
miCheckup presents the current Early Cancer Detection Test, including its intended use, workflow, limitations and clinical follow-up.
Visit miCheckupA repeatable development pattern
The research-to-application pathway can be applied to other disease branches as signatures, analytical methods and validation mature.
Explore the scientific roadmapWhat compounds
Every layer can make the next question more valuable.
The platform thesis is built around three forms of accumulating value,not around exposing a recurring-revenue mechanism to the customer.
Personal context
Repeated measurements can move interpretation from comparison with a population toward comparison with the person’s own established range.
Revisitable data
A broad historical profile may be re-examined when research identifies a new relationship,creating potential insight without recreating the earlier biological moment.
Multiple disease branches
The shared measurement and computational foundation can support focused tests across four major chronic disease areas as evidence develops.
1 → 4
One intelligence platform · Four major chronic disease areas
The branches make sense because the biological control layer is shared.
Oncology is the published foundation. Cardiovascular, neurodegenerative and metabolic research extend the same core idea: measure microRNA patterns, apply computational interpretation and validate each use independently.
See the system, not only the test
Explore how measurement, intelligence and history connect.
The broader miRoncol platform explains why the first oncology application is the beginning of the story,not the boundary of it.